Candriam S.C.A. Purchases 2,633 Shares of argenex SE $ARGX

Candriam S.C.A. raised its holdings in shares of argenex SE (NASDAQ:ARGX) by 5.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 48,200 shares of the company’s stock after acquiring an additional 2,633 shares during the quarter. Candriam S.C.A. owned approximately 0.08% of argenex worth $35,550,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently bought and sold shares of ARGX. Adage Capital Partners GP L.L.C. grew its position in shares of argenex by 114.3% during the second quarter. Adage Capital Partners GP L.L.C. now owns 297,113 shares of the company’s stock valued at $163,775,000 after purchasing an additional 158,476 shares in the last quarter. Franklin Resources Inc. boosted its position in argenex by 103.9% in the 2nd quarter. Franklin Resources Inc. now owns 279,803 shares of the company’s stock valued at $154,233,000 after buying an additional 142,606 shares during the period. Balyasny Asset Management L.P. grew its position in shares of argenex by 826.6% during the 2nd quarter. Balyasny Asset Management L.P. now owns 89,296 shares of the company’s stock worth $49,222,000 after buying an additional 79,659 shares in the last quarter. Hudson Bay Capital Management LP bought a new position in argenex in the second quarter worth approximately $37,441,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in argenex by 244.6% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 87,414 shares of the company’s stock valued at $48,184,000 after purchasing an additional 62,044 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on ARGX shares. JPMorgan Chase & Co. boosted their target price on shares of argenex from $925.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Monday, December 8th. Wedbush reaffirmed an “outperform” rating and issued a $1,000.00 price objective on shares of argenex in a report on Wednesday, January 14th. Robert W. Baird lowered shares of argenex from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 18th. TD Cowen upped their price objective on shares of argenex from $800.00 to $1,146.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Finally, Truist Financial boosted their target price on shares of argenex from $950.00 to $1,030.00 and gave the company a “buy” rating in a report on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $986.78.

argenex Price Performance

argenex stock opened at $828.24 on Tuesday. The stock’s fifty day moving average is $842.75 and its two-hundred day moving average is $795.35. The stock has a market cap of $51.25 billion, a PE ratio of 35.56, a P/E/G ratio of 0.70 and a beta of 0.37. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.